General and Administrative (G&A) Expenses: G&A expenses were $9.7 million for the quarter ended March 31, 2025, compared to $10.3 million for the quarter ended March 31, 2024. The decrease was ...

OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times ... Step 4: Preparing a Trial Balance After all transactions are logged ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and ...

InvestingPro data shows the company maintains strong financial health with more cash than debt on its balance sheet. The trial is evaluating the efficacy of DNTH103 in individuals with generalized ...

Good afternoon, everyone and thank you for joining our conference call to discuss BioStem Technologies' first quarter 2025 financial results and corporate highlights. Leading the call today will be ...

The trial is examining the safety ... This information is based on a press release statement from Phio Pharmaceuticals. For deeper insights into Phio’s financial health and 12 additional ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and Intern ...

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...

This press release statement outlines the potential of vidofludimus calcium as a novel treatment for PMS, based on the encouraging results from the phase 2 CALLIPER trial. With analyst price targets ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 ...

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...